Collagen is widely used as a medical device due to its biocompatible, biodegradable properties and its ability to promote tissue regeneration. Research, which is very active in this field, has developed a product that marks a breakthrough in the industry: it is called UniColl®, and in Italy, it is distributed by Giusto Faravelli SpA, where Martina Mastropasqua, Product Manager of the Pharma Division, is responsible for its promotion.
What are the properties of UniColl® that distinguish it from other collagen-based products?
UniColl®, developed by the German company KBM, is an innovative collagen that represents a significant advancement in the field of biomaterials due to its unique characteristics. It is a type I acid-soluble telocollagen (ASC) intended for use in medical devices, extracted from bovine hides sourced from TSE-BSE free certified countries, ensuring high safety and quality standards.
One of the distinctive features of UniColl® is the preservation of its native triple-helix structure, including the N and C-terminal telopeptides. This conformation allows for natural self-assembly into fibrils, a fundamental process that greatly expands the range of applications of the product in the medical device sector and in the production of materials for biomedical applications.
However, the real innovation lies in KBM’s ability to obtain collagen with extremely low levels of endotoxins, a unique achievement worldwide. This feature ensures an additional level of safety and quality, crucial for use in even invasive medical devices.
In summary, thanks to its purity, versatility, and safety, UniColl® stands out as an excellent solution for the development and design of cutting-edge medical devices and other applications in the biomedical sector.
What advantages does the low endotoxin profile of UniColl® offer?
The low endotoxin content of UniColl® is a key element for its use in medical devices and the biomedical sector. It allows for use in all types of medical devices, including invasive ones, significantly reducing the risk of inflammatory reactions. Thanks to this profile, UniColl® is ideal for applications in regenerative medicine, aesthetic medicine, and advanced biotechnology.
What are the most promising applications of UniColl®, such as wound healing, tissue reconstruction, and cell cultures?
The potential applications of UniColl® are vast and cutting-edge. Its unique characteristic of being endotoxin-free makes it stand out in the market, opening the door to many innovative applications.
For example, in regenerative medicine, it could be used in eye drops—combined with hyaluronic acid—or in specific patches for the treatment of open wounds, ensuring a more effective healing process. Additionally, its versatility makes it ideal for use in injections aimed at the reconstruction of tendons, cartilage, bones, and even teeth.
In the field of cell cultures, the low endotoxin content is an added value, as it provides a safe and optimal nutritional support for cell growth.
All of these areas are not only promising but also technologically advanced.
We are confident that as the market evolves, clients will recognize the innovative value of UniColl® and use it to create more efficient medical devices thanks to collagen’s presence.
How could UniColl®’s high solubility in acidic and aqueous solutions lead to new innovations?
UniColl®’s high solubility in slightly acidic and aqueous solutions makes it an extremely versatile material, expanding the possibilities for developing new formulations and medical devices.
Thanks to this property, it is possible, for example, to create solutions with varying collagen concentrations, adaptable to different pharmaceutical and biomedical applications.
Moreover, it allows for the production of three-dimensional matrices via freeze-drying, ideal for applications in tissue engineering and regenerative medicine, as well as the development of sterile solutions that can be easily sterilized by end-users.
Currently, UniColl® is available in the “substrate” version, i.e., in the form of collagen flakes in water; however, KBM’s ability to customize formulations paves the way for the development of innovative, high-performance medical devices destined to revolutionize the biomedical sector.
How does Faravelli Pharma Division plan to promote UniColl® in Italy to maximize its impact on the local market?
The distribution of UniColl® in Italy represents an exciting challenge for our division, not only because of the intrinsic value of the product but also because it opens the door to new opportunities in the biomaterials sector and allows us to explore new contacts in the medical device sector.
To maximize the impact on the local market, we will develop a targeted network of contacts in relevant application sectors, such as regenerative medicine, tissue engineering, and invasive devices.
At the same time, we will be present at major industry fairs and events, both nationally and internationally, alongside KBM, a partner capable of providing the technical and training support necessary to identify the best application solutions.
This approach will optimize the design and performance of medical devices by adapting the use of UniColl® to the specific needs of each project.
Thanks to this close collaboration between KBM, Faravelli Pharma Division, and clients, UniColl® will be effectively integrated into next-generation medical devices.
We are ready to embrace this challenge with enthusiasm and determination, confident that the value of UniColl® will be properly recognized in the medical device and biomedical application market.
Email: pharma@faravelli.it
Web: www.faravelligroup.com
